Yellow Eyes or Dark Urine — During Immunotherapy

Yellow eyes, yellow skin or unusually dark urine during immunotherapy usually points to immune-related hepatitis — liver inflammation caused by an overactive immune response, not by the cancer itself. It is one of the immune-related adverse events (irAEs) that checkpoint inhibitor immunotherapy can cause, and NCCN and ASCO guidance list it among the reactions that need prompt evaluation. Liver function tests (LFTs) confirm how much the liver is affected and help rule out other causes such as viral hepatitis, gallstones, or a reaction to an unrelated medicine. It is not something to wait out — a same-day blood test is the safest next step.

No. Jaundice or dark urine during immunotherapy should be treated as same-day urgent, not saved for your next appointment. By the time yellowing is visible, liver inflammation is usually more advanced than it would be if picked up on a routine blood test alone, so oncology teams ask patients to call or come in immediately rather than monitor at home. Go to the emergency room directly if jaundice comes with confusion, easy bruising or bleeding, severe abdominal pain, or vomiting — these can signal a more serious liver problem that needs immediate hospital care.

Your oncology team will usually order liver function tests and a hepatitis screen to confirm immune-related hepatitis and rule out other causes, then pause immunotherapy while your liver is monitored. Depending on how high the liver enzymes are and whether jaundice is present, care may involve close observation alone or a course of steroid medication to calm the immune reaction, decided and dosed by your treating oncologist. Most mild-to-moderate reactions improve with treatment; more severe cases are managed jointly with a liver specialist. Whether and when immunotherapy restarts is a case-by-case decision, never automatic.

Not necessarily the same mechanism, though the visible signs can look identical. Immune-related hepatitis happens because immunotherapy activates your immune system broadly, and that activation can turn against your own liver cells — different from the direct toxic effect some other medicines can have on the liver, or from viral hepatitis. Because the underlying cause changes the treatment (immune hepatitis often responds to steroid medication), your care team tests for the specific cause rather than assuming it, even though yellow eyes and dark urine look the same either way.

Sometimes, but it is never automatic and depends on how severe the reaction was and how well your liver recovers. For milder reactions that resolve fully once liver enzymes normalise, some patients are able to resume immunotherapy under closer monitoring. For more severe hepatitis, or if it recurs, your oncologist and tumour board weigh the benefit of continuing immunotherapy for your cancer against the risk of another, potentially worse, reaction. This decision is made individually, using your test results and overall treatment goals — never a fixed rule that applies to everyone.

No — jaundice is usually a later, visible sign. Earlier signs can include unusual tiredness, loss of appetite, nausea, mild discomfort under the right ribs, or pale stools, and often the very first sign is simply a raised liver enzyme result on a routine blood test with no symptoms at all. That's why immunotherapy programmes include scheduled liver function tests before each cycle even when you feel completely well — catching a rise in enzymes early, before jaundice develops, usually means an easier-to-manage reaction.